Markets

Flex LNG Ltd. announced the successful completion of a $175 million JOLCO lease financing for the Flex Courageous, generating $42 million in net proceeds and extending debt maturity to 2035, while reducing debt costs. This is the first step in the company’s refinancing program targeting three vessels with a 37-year backlog. Flex LNG plans to refinance two more vessels in 2025 to further strengthen its financial position, which is already robust with a cash balance of $410 million.

Xiaomi founder Lei Jun responded to criticisms regarding its EV market entry with social media posts. He echoed resilience, emphasizing “opportunities for those who come later”. This followed remarks from a rival executive appearing to target Xiaomi’s success. Lei Jun also shared a quote about criticism signifying influence, indicating the company views scrutiny positively while acknowledging user support.

Jia Yueting, co-founder of Faraday Future (FF), reaffirmed his commitment to shareholders and investors. He aims to achieve the initial milestones of his equity incentive plan, linked to FF’s stock performance and market capitalization. FF announced pre-orders for its FX Super One and unveiled the design rendering of the FX4. Upcoming plans include launch events and expanding sales initiatives, with a focus on web3 collaborations and a rollout in the Middle East.

A recent report reveals the significant dependence of U.S. consumers on Chinese-made goods. Highlighting items like baby strollers, artificial plants, and umbrellas, the study underscores China’s dominance in various consumer markets. An experiment demonstrated consumers’ preference for cheaper, Chinese-made products, even when an American-made alternative was available at a higher price. The article suggests a full transition away from Chinese imports is complex.

Elon Musk launched XChat, an encrypted messaging platform for X (formerly Twitter), featuring end-to-end encryption, self-destructing messages, file sharing, and audio/video calls without phone numbers. Built with Rust and “bitcoin-like” encryption, it aims to become an all-encompassing “everything app” like WeChat. Currently, XChat is available to select paying users and secured with a passcode, representing a major step in Musk’s broader strategy for the platform.

Faraday Future’s Stockholders’ Day highlighted its commitment to transparency and shareholder value. The FX Super One will launch with exclusive events in June and July, followed by a B2C rollout. The company has secured over 2,500 B2B pre-order deposits for the FX Super One, and unveiled the FX 4 design concept. FF is also expanding operations, including a new Middle East facility, and enhancing its tech and operational capabilities.

Google launched the AI Edge Gallery, an app enabling on-device AI on smartphones. Sourced from Hugging Face, it allows users to run AI models offline with features like image-based question answering and text manipulation via a “Prompt Lab.” Performance varies based on device hardware and model size. The app is an experimental Alpha version, open-source under Apache 2.0, and encourages user feedback.

Hyundai Card has earned the UL Verified Healthy Building Mark for four of its facilities in Seoul, becoming the first cultural and leisure buildings in Asia to receive this certification. This achievement highlights their dedication to employee and guest well-being through healthier and more sustainable indoor environments, evaluated for air and water quality, as well as overall indoor environment.

Trevi Therapeutics will release topline results from its Phase 2b CORAL trial of Haduvio, an investigational therapy for chronic cough in idiopathic pulmonary fibrosis (IPF). A conference call and webcast will be held on June 2nd, 2025, at 8:30 a.m. ET to discuss the findings. Haduvio targets the cough reflex arc, and initial trials show promising reduction in cough frequency. The results are highly anticipated as there is currently no approved therapy for IPF chronic cough. Further information can be found on the company’s website.

Bicara Therapeutics presented positive Phase 1/1b trial data for ficerafusp alfa, a bifunctional antibody, combined with pembrolizumab in first-line recurrent/metastatic head and neck cancer. The results, particularly in HPV-negative patients, showed significant antitumor activity, including a median duration of response of 21.7 months, median overall survival of 21.3 months, and a two-year overall survival rate of 46%. The data supports the advancement of the FORTIFI-HN01 pivotal trial.